Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10010780 | 0.94 | CPT2 (0.36) | CPT2ALDH1A1FFAR1TDP1TSHR | |
| SCHEMBL10011226 | 0.88 | MEN1 (0.37) | CPT2ALDH1A1FFAR1TDP1TSHR | |
| SCHEMBL10012165 | 0.86 | CYP1A2 (0.31) | CPT2CYP2D6CYP2C19ACLY | |
| SCHEMBL10010812 | 0.84 | TSHR (0.38) | CPT2ALDH1A1FFAR1TDP1TSHR | |
| SCHEMBL10012171 | 0.81 | CYP1A2 (0.33) | CPT2FFAR1TDP1CYP2D6CYP2C19 | |
| SCHEMBL10012269 | 0.79 | MEN1 (0.40) | CPT2ALDH1A1FFAR1TDP1TSHR | |
| SCHEMBL10011026 | 0.77 | MEN1 (0.34) | TSHRCYP2D6CYP2C19HIF1AMEN1 | |
| SCHEMBL10012004 | 0.74 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL10654543 | 0.73 | BLM (0.39) | CPT2ALDH1A1FFAR1TDP1TSHR | |
| SCHEMBL285165 | 0.72 | TDP1 (0.41) | CPT2ALDH1A1FFAR1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9130244-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | SLC8A1, OR10J3, SLC8B1 | CPT2 1719/4885ALDH1A1 2965/4885FFAR1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.